This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

A Second View: Understanding the recent label expansion of LILETTA (levonorgestrel-releasing intrauterine system), from Abbvie and Medicines360 as a treatment for heavy menstrual bleeding.

Ticker(s): ABBV

Who's the expert?

Institution: Advantia Health

  • Gynecologist at Advantia Health in the Washington DC area.
  • Manages several patients for heavy menstrual bleeding.
  • Has utilized hundreds of Liletta IUDs in patients.

Interview Goal
To discuss the standard of care and the use of LILETTA (levonorgestrel-releasing intrauterine system), from Abbvie and Medicines360 as a treatment for heavy menstrual bleeding.

Do you want answers to these questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.